Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of ...

Weight loss goals may be at the forefront of many New ... Eli Lilly’s gains of +200%. Eli Lilly does appear to have the advantage as it relates to expansion in the weight loss drug market ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Eli Lilly is being advised by JPMorgan. Eli Lilly and JPMorgan declined to comment. Scorpion did not respond to requests for comment. Scorpion’s lead drug inhibits a protein mutation that is a ...

Ricks, Lilly chair and CEO, will participate in a fireside chat on Tuesday, Jan. 14 at 5:15 p.m. Eastern time. Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug ...